TAI · 3054.TW
LIWANLI Innovation Co., Ltd.
NT$57.00-NT$0.50 (-0.87%)
LIWANLI Innovation Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.63% below the high.
Loading market information…
TWO · 1796.TWO · TWD
Stock price, dividends
Quote as of Oct 30, 2026, 05:23 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
GeneFerm Biotechnology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.1% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
GeneFerm Biotechnology Co., Ltd.’s forward annual dividend is NT$2.00 per share, paid annual. The forward yield is 7.34% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
THE COMPANY BEHIND THE TICKER
GeneFerm Biotechnology Co., Ltd. specializes in the development, production, and global distribution of fermented health and wellness products, serving both the Taiwanese domestic market and international clients. The company's extensive product line includes a variety of microbial fermentation offerings such as different types of mushrooms, lactic acid bacteria, other bacterial strains, yeast, and algae. Furthermore, GeneFerm provides a wide array of bio-fermented ingredients, including specialized powders like nattomena, natto fermented powder, red yeast rice fermented powder, and various mycelial powders (e.g., antrodia cinnamomea, cordyceps, reishi, phellinus linteus, armillaria mellea). They also supply beta-glucan powder, fermented fruit and vegetable enzymes, as well as probiotic and peptide components. Beyond its product sales, GeneFerm offers additional services such as private label supplement manufacturing, packaging equipment, and expert microbial fermentation toll manufacturing and consulting. Established in 1988, the company maintains its headquarters in Tainan City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$57.00-NT$0.50 (-0.87%)
LIWANLI Innovation Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.63% below the high.
NT$23.95-NT$0.10 (-0.42%)
Allied Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 35.01% below the high.
NT$55.70+NT$0.80 (+1.46%)
TSH Biopharm Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 6.07% below the high.
NT$16.80-NT$0.25 (-1.47%)
OK Biotech Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 8.75% below the high.
NT$44.20+NT$1.35 (+3.15%)
BenQ Medical Technology Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.42% below the high.
NT$72.10-NT$0.40 (-0.55%)
Crystalvue Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 13.45% below the high.
NT$9.42-NT$0.25 (-2.59%)
Sunny Pharmtech Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.54% below the high.
NT$9.88-NT$0.06 (-0.6%)
InnoPharmax Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.4% below the high.
